Latest Headlines

  1. Novartis Announces New Radioligand Therapy Manufacturing Facility In Denton, Texas 2/26/2026

    Novartis, a leading global innovative medicines company, today announced plans to establish a new 46,000-square-foot radioligand therapy (RLT) manufacturing site in Denton, Texas. 

  2. Quotient Sciences Extends Commercial Manufacturing Partnership For Ultra-Rare Disease Treatment 2/26/2026

    Quotient Sciences, a leading integrated CRDMO, announced an extended commercial supply partnership with Ipsen, a global biopharmaceutical company, to manufacture a treatment for Fibrodysplasia Ossificans Progressiva (FOP), an ultra-rare disease affecting fewer than 1,000 people worldwide.

  3. Bora Pharmaceuticals And GSK Sign $250M Five Year Global Manufacturing Contract 2/24/2026

    This renewed collaboration reinforces the long-standing relationship between the two companies and expands the partnership, allowing GSK access to multiple sites within the Bora network, including its newest OSD site in Maple Grove, Minnesota.

  4. AbbVie Announces $380 Million Investment With Two New Active Pharmaceutical Ingredient Manufacturing Facilities In Illinois 2/24/2026

    AbbVie (NYSE: ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. These new state-of-the-art facilities will integrate advanced manufacturing technologies with artificial intelligence (AI) to support the production of AbbVie's next-generation neuroscience and obesity medications.

  5. Johnson & Johnson Announces $1 Billion Investment With New Cell Therapy Manufacturing Facility In Pennsylvania 2/22/2026

    ohnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. This new facility will further expand the Company’s U.S. manufacturing capacity as it advances its industry leading portfolio and pipeline of transformational medicines for cancer, immune-mediated and neurological diseases.

  6. Esco Philippines Returns To The 41st PSNM Annual Convention: Supporting Innovation In Nuclear Medicine 2/19/2026
  7. Syntegon Launches AIM9 High-Speed Inspection Platform 2/18/2026

    Based on decades of experience and proven technology, Syntegon is launching the AIM9 inspection platform. It combines visual inspection and leak detection with outputs of up to 600 vials per minute, helping pharmaceutical manufacturers and CMOs achieve the highest inspection and product quality.

  8. JHS CEO Chris Preti Receives 2026 Person Of Influence Award 2/12/2026

    Spokane, WA. - The Spokane Journal of Business named Chris Preti, CEO of Jubilant HollisterStier (JHS), as one of its 2026 People of Influence.

  9. Subcutaneously Administered Nanotrastuzumab Matches Performance Of Herceptin HYLECTA In Minipig Study 2/12/2026

    Nanoform Finland Plc, the medicine performance-enhancing company, announced the results from a preclinical study designed to compare the tolerability and pharmacokinetics of Nanotratsuzumab, a nanoformed, novel, hyaluronidase-free, non-aqueous nanoparticle suspension of trastuzumab for subcutaneous delivery versus Herceptin HYLECTA™, a co-formulated product with Halozyme’s proprietary hyaluronidase enzyme marketed by Roche/Genentech.

  10. A New Chapter In ROIS Commercial Leadership 2/11/2026

    ROIS today announced the appointment of Kimberlee Steele as Chief Commercial Officer, effective from 1 March 2026.